pdf   xlsx method abbreviations

metastatic/advanced UC (mUC) - 2nd Line (L2), atezolizumab based treatment , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.85 [0.73, 0.99]< 10%1 study (1/-)98.2 %NAnot evaluable crucial-
deaths (OS) (extension) 0.82 [0.71, 0.94]< 10%1 study (1/-)99.7 %NAnot evaluable important-
progression or deaths (PFS) 0.89 [0.60, 1.32]< 10%1 study (1/-)71.3 %NAnot evaluable important-
DOR 0.16 [0.07, 0.35]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
objective responses (ORR) 0.99 [0.68, 1.45]> 10%1 study (1/-)48.5 %NAnot evaluable non important-

safety endpoints 00

AE (any grade) 0.38 [0.17, 0.88]< 10%1 study (1/-)98.9 %NAnot evaluable non important-
AE (grade 3-4) 0.80 [0.62, 1.04]< 10%1 study (1/-)94.9 %NAnot evaluable non important-
AE leading to death (grade 5) 0.91 [0.46, 1.79]< 10%1 study (1/-)61.0 %NAnot evaluable non important-
AE leading to treatment discontinuation (any grade) 0.37 [0.24, 0.57]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
SAE (any grade) 0.92 [0.70, 1.19]< 10%1 study (1/-)74.4 %NAnot evaluable non important-
STRAE (any grade) 0.56 [0.40, 0.78]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
TRAE (any grade) 0.28 [0.19, 0.40]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
TRAE (grade 3-4) 0.33 [0.25, 0.45]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
TRAE leading to death (grade 5) 0.42 [0.13, 1.39]< 10%1 study (1/-)92.2 %NAnot evaluable non important-
TRAE leading to discontinuation (any grade) 0.22 [0.12, 0.38]< 10%1 study (1/-)100.0 %NAnot evaluable non important-

TRAE (grade 3-4) endpoints 00

Anaemia TRAE (grade 3-4) 0.40 [0.18, 0.89]< 10%1 study (1/-)98.8 %NAnot evaluable non important-
Asthenia TRAE (grade 3-4) 0.42 [0.18, 0.97]< 10%1 study (1/-)97.8 %NAnot evaluable non important-
Constipation TRAE (grade 3-4) 0.02 [0.00, 0.38]< 10%1 study (1/-)99.5 %NAnot evaluable non important-
Fatigue TRAE (grade 3-4) 0.37 [0.15, 0.88]< 10%1 study (1/-)98.7 %NAnot evaluable non important-
Febrile neutropenia TRAE (grade 3-4) 0.04 [0.00, 0.27]< 10%1 study (1/-)99.9 %NAnot evaluable non important-
Neutropenia TRAE (grade 3-4) 0.04 [0.01, 0.15]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
Peripheral neuropathy TRAE (grade 3-4) 0.12 [0.01, 0.95]< 10%1 study (1/-)97.7 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons